AliveDx Suisse S.A. and Everlight Biotech Co. Ltd. have signed a distribution agreement, which will enable Everlight Biotech Co. Ltd. to distribute the MosaiQ® solution in Taiwan. The distribution agreement takes effect immediately.
AliveDx is dedicated to expanding its reach and presence across various regions. This strategic collaboration with a prominent partner in Taiwan underscores the company’s commitment to supporting the healthcare sector and enhancing patient care.
The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.
“AliveDx’s partnership with Everlight Biotech is another strategic step that reaffirms our commitment to global expansion. We look forward to introducing our MosaiQ solution to the Taiwanese market and to creating clinical and economical value for clinicians, helping them to shorten the time to diagnosis,” said Manuel O. Méndez, AliveDx’s CEO.
Everlight Biotech Co. Ltd. is a reputed importer and distributor of innovative IVD and medical technology solutions in Taiwan. Their portfolio includes high-quality IVD solutions, clinical diagnostics, laboratory equipment, consumables, chemicals, and reagents.
“We are honored to collaborate with AliveDx. We believe that MosaiQ’s innovative microarray multiplexing diagnostic solutions will further strengthen our portfolio and enable us to provide the Taiwan healthcare sector with the latest, best-in-class technologies that will have a positive impact on patients,” said Mr. Bert Huang, Chairman, Everlight Biotech Group.
To learn more, please visit the Everlight Biotech website.
